Trending...
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
- Colorado Springs: Mayor Yemi issues statement following discharge from UCHealth Memorial Hospital Central
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.
BD SpectralFX™ Technology maximizes the number of colors that can be used in flow cytometry, allowing scientists to analyze up to 50 or more characteristics of a single cell at one time, with optimal resolution and sensitivity, which is ideal for scientists pursuing novel biomarker discovery. BD CellView™ Image Technology enables high-speed fluorescent and label-free imaging of single cells, revealing precise spatial and morphological insights – like the location of a virus or protein within a single cell, or the microscopic interaction between two cells – that can be visually confirmed and analyzed in real time. Combining these technologies, which were first introduced in the BD FACSDiscover™ S8 Cell Sorter and profiled on the cover of the journal Science, the BD FACSDiscover™ A8 Cell Analyzer enables scientists to capture more insights per experiment than ever, with exceptional depth, speed and sensitivity.
Additional advancements on the BD FACSDiscover™ A8 Cell Analyzer are specifically designed to power translational research. Highlights include:
"The BD FACSDiscover™ A8 Cell Analyzer signals an exciting step forward for researchers in areas like immuno-oncology that require tools delivering excellent reproducibility and performance, while managing budget constraints," said Rui Gardner, head of Flow Cytometry Core Facility at Memorial Sloan Kettering Cancer Center, an early access collaboration site. "Our investigators have already learned so much using this new technology, and we look forward to performing deep immunophenotyping for high-fidelity biomarker discovery to elucidate insights that can advance research and improve human health."
More on Colorado Desk
Steve Conly, worldwide president of BD Biosciences, added, "Translational research, in particular, is growing at a rapid pace and the BD FACSDiscover™ A8 Cell Analyzer combines advanced science with ease of use to empower, like never before, scientists developing the next generation of potentially life-changing therapies. Paired with the BD FACSDiscover™ S8 Cell Sorter, and alongside our advancements in software, informatics, and reagents, this landmark cell analyzer will enable new dimensions of possibilities in one state-of-the-art ecosystem."
New software innovations launching alongside the instrument include the latest version of BD FACSChorus™ Software, which simplifies workflows on both the BD FACSDiscover™ A8 Cell Analyzer as well as FACSDiscover™ S8 Cell Sorter, and the faster, easier-to-use analysis software FlowJo™ v11. All three products will be featured at the International Society for Advancement of Cytometry CYTO 2025 event at booth 615 from May 31 to June 4 in Denver. The BD FACSDiscover™ A8 Cell Analyzer is now available to order through local sales representatives, and through a forthcoming FACSDiscover™ Partner Program initially in select regions that gives customers added flexibility and support. More information is available at bdbiosciences.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
More on Colorado Desk
SOURCE BD (Becton, Dickinson and Company)
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.
BD SpectralFX™ Technology maximizes the number of colors that can be used in flow cytometry, allowing scientists to analyze up to 50 or more characteristics of a single cell at one time, with optimal resolution and sensitivity, which is ideal for scientists pursuing novel biomarker discovery. BD CellView™ Image Technology enables high-speed fluorescent and label-free imaging of single cells, revealing precise spatial and morphological insights – like the location of a virus or protein within a single cell, or the microscopic interaction between two cells – that can be visually confirmed and analyzed in real time. Combining these technologies, which were first introduced in the BD FACSDiscover™ S8 Cell Sorter and profiled on the cover of the journal Science, the BD FACSDiscover™ A8 Cell Analyzer enables scientists to capture more insights per experiment than ever, with exceptional depth, speed and sensitivity.
Additional advancements on the BD FACSDiscover™ A8 Cell Analyzer are specifically designed to power translational research. Highlights include:
- High-throughput, walkaway automation that enables best-in-class cost-per-insight economics
- New intuitive software workflows that allow for effective management of large datasets, for improved system usability
- Seamless pairing with the industry-leading ecosystem of BD FACSDiscover™ Cell Sorters and BD Reagents
"The BD FACSDiscover™ A8 Cell Analyzer signals an exciting step forward for researchers in areas like immuno-oncology that require tools delivering excellent reproducibility and performance, while managing budget constraints," said Rui Gardner, head of Flow Cytometry Core Facility at Memorial Sloan Kettering Cancer Center, an early access collaboration site. "Our investigators have already learned so much using this new technology, and we look forward to performing deep immunophenotyping for high-fidelity biomarker discovery to elucidate insights that can advance research and improve human health."
More on Colorado Desk
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Colorado: NGA Issues Statement on Political Shootings in Minnesota
Steve Conly, worldwide president of BD Biosciences, added, "Translational research, in particular, is growing at a rapid pace and the BD FACSDiscover™ A8 Cell Analyzer combines advanced science with ease of use to empower, like never before, scientists developing the next generation of potentially life-changing therapies. Paired with the BD FACSDiscover™ S8 Cell Sorter, and alongside our advancements in software, informatics, and reagents, this landmark cell analyzer will enable new dimensions of possibilities in one state-of-the-art ecosystem."
New software innovations launching alongside the instrument include the latest version of BD FACSChorus™ Software, which simplifies workflows on both the BD FACSDiscover™ A8 Cell Analyzer as well as FACSDiscover™ S8 Cell Sorter, and the faster, easier-to-use analysis software FlowJo™ v11. All three products will be featured at the International Society for Advancement of Cytometry CYTO 2025 event at booth 615 from May 31 to June 4 in Denver. The BD FACSDiscover™ A8 Cell Analyzer is now available to order through local sales representatives, and through a forthcoming FACSDiscover™ Partner Program initially in select regions that gives customers added flexibility and support. More information is available at bdbiosciences.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
More on Colorado Desk
- Colorado: Governor Polis Statement on Assassination of Minnesota Elected Official & Husband, and Attempt on Life of Another Elected Official & Family
- Colorado Springs: Westside Community "Saleabration" Block Party to take place Saturday
- Colorado Springs: Dublin Boulevard closure starts Monday evening
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- Colorado: Governor Polis Appoints Kimbra L. Killin to the 13th Judicial District Court
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
[email protected] | [email protected] |
SOURCE BD (Becton, Dickinson and Company)
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Optical Engines Launches Polarium: The Highest Average Power Ultrafast Laser
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
- IFFA 2025 Shines Bright as Mukesh Modi Welcomes Rio Rocket and Award Winner Lulu Lopez
- Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
- Colorado Springs: City announces online survey and public meeting dates for Park System Master Plan Process
- Colorado Springs: Mountain Metro celebrates free summer rides
- City of Colorado Springs to host Quarterly ADA Forum Thursday
- Colorado Springs Airport Launches International Flight with Southwest Airlines
- WOA Entertainment Group Unveils Independent No.1's: Breakthrough Artists II —A Celebration of Indie Excellence
- SheepFeast Launches "1 Million Discipled" Global Initiative to Empower Disciple-Making Around the World
- Sun City Resident Realtor Launches Exclusive Weekly Market Update for Bluffton's 55+ Communities!
- Delta Capital Group, Inc. Earns A+ Rating from the Better Business Bureau, Marking Another Milestone in Explosive Growth
- International AI and SEO Expert Chris Raulf to Speak on GEO and AI-Driven SEO at DigiMarCon 2025
- Vice President JD Vance & Industry Leaders at Bitcoin Conference After Partnership Signing to Optimize Cybersecurity Solutions: Bullet Blockchain, Inc
- Actress/Comedian Schelle Purcell Sizzles This Summer with Star-Making Turn in Tyler Perry's #1 Netflix Film, Straw, and Upcoming Comedy Special
- Braxus Entertainment Group Acquires All Star Events